Alvotech [NASDAQ: ALVO]
Adopting Blockchain Technology for Clinical Trial Management
Tomaz Vaupotic
Dr. Tomaz Vaupotic is a senior director of clinical and medical quality at Alvotech. Over the past decade, by working at Alexion, Takeda and Sandoz, Tomaz dedicated his endeavours to promoting scientific integrity of clinical and medical evidence generation to ultimately benefit public trust in medical research, better treatment outcomes and sustainability of healthcare systems. Opinions are my own and not the views of my employer.
Impact of Blockchain Technology on the Integrity and Transparency of Clinical Trial Data Management
Blockchain technology is poised to significantly impact the integrity and transparency of clinical trials as well as real-world evidence (RWE)--based medical research by providing a secure and immutable platform for data management and sharing. Through its decentralised nature and cryptographic mechanisms, blockchain ensures that data derived from clinical trials and medical research remains tamper-proof and verifiable, thereby enhancing data integrity and public trust in evidence-based medicine. This aspect is particularly crucial in ensuring the credibility of clinical trial results and protecting against data manipulation or fraud.
Furthermore, blockchain facilitates transparent and auditable data sharing among relevant stakeholders, including researchers, participants, regulators and sponsors. By enabling real-time access to authenticated trial data while maintaining privacy through encryption techniques, blockchain enhances transparency throughout the trial lifecycle. This transparency fosters greater trust among stakeholders and allows for more informed decision-making regarding trial participation, protocol design, and regulatory compliance.
Clearly define the research objectives and outcomes desired from leveraging real-world evidence. Establishing specific goals will guide the selection of appropriate data sources and methodologies.
Moreover, blockchain's ability to streamline processes such as patient consent management, randomisation, and supply chain tracking can further enhance the efficiency and reliability of clinical trials. By automating and digitising these processes, blockchain reduces administrative burdens, minimises errors and increases the traceability of trial activities.
Overall, blockchain technology holds immense promise in revolutionising the conduct of clinical trials by bolstering integrity, transparency, and efficiency across the research ecosystem. However, continued research, collaboration between the regulators and the industry, and standardisation efforts are essential to realise the full potential of blockchain in transforming the clinical trial landscape.
Challenges in Adopting Blockchain Technology for Clinical Trial Management
Several challenges emerge in adopting blockchain technology for clinical and medical evidence generation. First and foremost, regulatory compliance, namely, regulatory frameworks governing clinical trials, varies across jurisdictions and, in many cases, hardly cope with the rapid advancements in technology. While financial market regulators have become increasingly vigilant of blockchain's opportunities, integrating blockchain into existing regulatory frameworks for clinical trials and data privacy, laws still pose a significant challenge.
Next, the lack of interoperability and standardisation among different blockchain platforms and electronic health record systems complicates data sharing and integration efforts within the clinical trial ecosystem.
Scalability issues inherent in blockchain technology, such as network congestion and transaction processing speed, may hinder its widespread adoption for managing large-scale clinical trials with extensive data volumes.
Cost and infrastructure: The initial setup costs associated with implementing blockchain infrastructure, including hardware, software, and especially personnel training, can be prohibitive for smaller research and biotech organisations with limited resources.
Therefore, it is very likely that early adopters of blockchain in medical research will be big pharma and large national and supra-national big data consortia.
User adoption and education about the benefits and intricacies of blockchain technology and overcoming resistance to change among clinicians, researchers, and participants are crucial for successful adoption. While blockchain offers enhanced security through its cryptographic features, ensuring data privacy and protection against unauthorised must remain in focus, particularly regarding sensitive patient information, which is paramount to the integrity of data.
This requires that so-called smart contracts, which automate and enforce the terms of agreements on the blockchain, must be rigorously tested and audited before deployment as well as in use to ensure their reliability and accuracy in executing protocols of complex clinical trials and real-world evidence-generating platforms. This further expands to address any ethical concerns related to data ownership and consent management.
Navigating these challenges will require collaborative efforts among researchers, industry stakeholders, regulatory bodies, and technology providers to develop tailored solutions and frameworks that address the unique requirements of clinical and medical evidence generation while harnessing the transformative potential of blockchain technology.
Landscape of Real-World Evidence Evolving in the Future
The landscape of real-world evidence is definitely expected to evolve significantly in the future, with several key trends and implications for the healthcare industry. RWE is becoming more widely adopted and integrated into healthcare decision-making processes across various stakeholders, including healthcare providers, regulators, payers, and policymakers. RWE, combined with advancement in diagnostics, is also facilitating the long-awaited transition towards personalised and precision medicine. This personalised approach to healthcare will eventually lead to more targeted interventions, improved patient outcomes, and optimised resource allocation.
Advice to Healthcare Professionals and Researchers Seeking to Leverage Real-World Evidence in Their Work
(i) Clearly define the research objectives and outcomes desired from leveraging real-world evidence. Establishing specific goals will guide the selection of appropriate data sources and methodologies.
(ii) Prioritise only high-data quality sources to ensure the reliability, accuracy, and completeness of real-world data and implement robust data validation and cleaning processes to mitigate biases and errors.
(iii). Leverage advanced analytical techniques such as machine learning, natural language processing, and predictive modelling to extract meaningful insights from complex real-world datasets and uncover hidden patterns. These are prerequisites for translating real-world evidence findings into actionable insights and recommendations for healthcare decision-makers, policymakers, and stakeholders to inform clinical practice, healthcare policy, and resource allocation.
For healthcare professionals in routine practice on a primary and secondary level, it will be essential to embrace a culture of continuous learning and understanding of research methodologies and data collection processes to maximise learnings from real-world experiences and to effectively harness the power of real-world evidence to drive evidence-based decision-making, improve patient outcomes, and advance healthcare delivery and innovation.
